Compare · ARA vs FMS
ARA vs FMS
Side-by-side comparison of American Renal Associates Holdings, Inc (ARA) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARA and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS carries a market cap of $12.31B.
- FMS has hit the wire 9 times in the past 4 weeks while ARA has been quiet.
- FMS has more recent analyst coverage (21 ratings vs 0 for ARA).
- Company
- American Renal Associates Holdings, Inc
- Fresenius Medical Care AG
- Price
- -
- $22.02+0.41%
- Market cap
- -
- $12.31B
- 1M return
- -
- +4.78%
- 1Y return
- -
- -23.15%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 21
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest ARA
- SEC Form 15-12B filed
- SEC Form EFFECT filed
- SEC Form SC 13G/A filed
- SEC Form 4 filed by P L Partners Capital Centerbridge
- SEC Form 4: W Thomas Erickson disposed to the issuer $0 worth of Common Stock (67,755 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: J Christopher Hocevar disposed to the issuer $0 worth of Common Stock (18,679 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: A Joseph Carlucci disposed to the issuer $0 worth of Common Stock (1,245,164 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: M John Jureller disposed to the issuer $0 worth of Common Stock (49,435 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: T Syed Kamal disposed to the issuer $0 worth of Common Stock (1,291,236 units at $0.00), decreasing ownership by 100% to 0 units
- SEC Form 4: Victoria Labriola disposed to the issuer $0 worth of Common Stock (64,569 units at $0.00), decreasing ownership by 100% to 0 units
Latest FMS
- Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
- SEC Form SD filed by Fresenius Medical Care AG
- Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
- Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
- Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
- SEC Form 6-K filed by Fresenius Medical Care AG